Clinical Trial Update: Spironolactone and Prevention of Calcineurin Inhibitor Toxicity in Kidney Transplant Recipients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating spironolactone to prevent calcineurin inhibitor toxicity in kidney transplant recipients has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Spironolactone (spironolactone)

Snippet

Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez | Conditions: Kidney Transplant | Phase 2 | Status: SUSPENDED